WO2008076255A3 - Lymphopoïétine stromale thymique (tslp) canine et utilisations associées - Google Patents

Lymphopoïétine stromale thymique (tslp) canine et utilisations associées Download PDF

Info

Publication number
WO2008076255A3
WO2008076255A3 PCT/US2007/025318 US2007025318W WO2008076255A3 WO 2008076255 A3 WO2008076255 A3 WO 2008076255A3 US 2007025318 W US2007025318 W US 2007025318W WO 2008076255 A3 WO2008076255 A3 WO 2008076255A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
canine
canine tslp
thymic stromal
peptide fragments
Prior art date
Application number
PCT/US2007/025318
Other languages
English (en)
Other versions
WO2008076255A2 (fr
Inventor
Jeanine D Mattson
Daniel M Gorman
Waal Malefyt Rene De
Mohamad A Morsey
Original Assignee
Schering Plough Ltd
Jeanine D Mattson
Daniel M Gorman
Waal Malefyt Rene De
Mohamad A Morsey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN2007800512690A priority Critical patent/CN101631800B/zh
Priority to BRPI0720001-3A2A priority patent/BRPI0720001A2/pt
Application filed by Schering Plough Ltd, Jeanine D Mattson, Daniel M Gorman, Waal Malefyt Rene De, Mohamad A Morsey filed Critical Schering Plough Ltd
Priority to NZ578352A priority patent/NZ578352A/en
Priority to IN3372CHN2009 priority patent/IN2009CN03372A/en
Priority to MX2009006470A priority patent/MX2009006470A/es
Priority to ES07867705.1T priority patent/ES2582655T3/es
Priority to CA2671865A priority patent/CA2671865C/fr
Priority to JP2009541349A priority patent/JP2010512744A/ja
Priority to KR1020097014362A priority patent/KR101525631B1/ko
Priority to AU2007334531A priority patent/AU2007334531B2/en
Priority to EP07867705.1A priority patent/EP2104683B1/fr
Publication of WO2008076255A2 publication Critical patent/WO2008076255A2/fr
Publication of WO2008076255A3 publication Critical patent/WO2008076255A3/fr
Priority to IL199170A priority patent/IL199170A/en
Priority to ZA2009/04152A priority patent/ZA200904152B/en
Priority to IL215507A priority patent/IL215507A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/43—Sweetening agents, e.g. thaumatin, monellin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5418—IL-7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne une protéine TSLP canine et un acide nucléique codant pour cette protéine. L'invention concerne également des fragments peptidiques de ladite protéine renfermant des épitopes spécifiques de la protéine TSLP canine. Cette protéine TSLP canine et les fragments peptidiques associés peuvent être utilisés comme antigène pour des dosages immunologiques et pour des vaccins induisant des anticorps anti-TSLP. L'invention concerne également des méthodes de production et d'utilisation du gène de la TSLP canine, de la protéine TSLP canine et des fragments peptidiques associés.
PCT/US2007/025318 2006-12-14 2007-12-11 Lymphopoïétine stromale thymique (tslp) canine et utilisations associées WO2008076255A2 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
KR1020097014362A KR101525631B1 (ko) 2006-12-14 2007-12-11 개 흉선 간질 림포포이에틴 단백질 및 이의 용도
JP2009541349A JP2010512744A (ja) 2006-12-14 2007-12-11 イヌの胸腺間質リンホポエチンタンパク質およびその使用
NZ578352A NZ578352A (en) 2006-12-14 2007-12-11 Canine thymic stromal lymphopoietin protein and uses thereof
BRPI0720001-3A2A BRPI0720001A2 (pt) 2006-12-14 2007-12-11 Proteína linfopoietin estromal tímica canina e usos da mesma
MX2009006470A MX2009006470A (es) 2006-12-14 2007-12-11 Proteina linfopoyetina estromatica timica de canino, y usos de la misma.
ES07867705.1T ES2582655T3 (es) 2006-12-14 2007-12-11 Proteína linfopoyetina estromal tímica canina y usos de la misma
AU2007334531A AU2007334531B2 (en) 2006-12-14 2007-12-11 Canine thymic stromal lymphopoietin protein and uses thereof
CN2007800512690A CN101631800B (zh) 2006-12-14 2007-12-11 犬胸腺基质淋巴细胞生成素蛋白及其应用
IN3372CHN2009 IN2009CN03372A (fr) 2006-12-14 2007-12-11
CA2671865A CA2671865C (fr) 2006-12-14 2007-12-11 Lymphopoietine stromale thymique (tslp) canine et utilisations associees
EP07867705.1A EP2104683B1 (fr) 2006-12-14 2007-12-11 Lymphopoïétine stromale thymique (tslp) canine et utilisations associées
IL199170A IL199170A (en) 2006-12-14 2009-06-04 Tymic stromal lymphopoietin (tslp) canine protein and its uses
ZA2009/04152A ZA200904152B (en) 2006-12-14 2009-06-12 Canine thymic stromal lymphopoietin protein and uses thereof
IL215507A IL215507A0 (en) 2006-12-14 2011-10-03 Canine thymic stromal lymphopoietin protein and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87513506P 2006-12-14 2006-12-14
US60/875,135 2006-12-14

Publications (2)

Publication Number Publication Date
WO2008076255A2 WO2008076255A2 (fr) 2008-06-26
WO2008076255A3 true WO2008076255A3 (fr) 2008-09-18

Family

ID=39430681

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/025318 WO2008076255A2 (fr) 2006-12-14 2007-12-11 Lymphopoïétine stromale thymique (tslp) canine et utilisations associées

Country Status (18)

Country Link
US (3) US7718772B2 (fr)
EP (1) EP2104683B1 (fr)
JP (4) JP2010512744A (fr)
KR (1) KR101525631B1 (fr)
CN (2) CN101631800B (fr)
AU (1) AU2007334531B2 (fr)
BR (1) BRPI0720001A2 (fr)
CA (1) CA2671865C (fr)
CO (1) CO6210756A2 (fr)
ES (1) ES2582655T3 (fr)
IL (2) IL199170A (fr)
IN (1) IN2009CN03372A (fr)
MX (1) MX2009006470A (fr)
NZ (1) NZ578352A (fr)
RU (2) RU2457217C2 (fr)
UA (3) UA108064C2 (fr)
WO (1) WO2008076255A2 (fr)
ZA (1) ZA200904152B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2671865C (fr) * 2006-12-14 2017-01-10 Schering-Plough Ltd. Lymphopoietine stromale thymique (tslp) canine et utilisations associees
JP5492158B2 (ja) * 2011-08-24 2014-05-14 富士フイルム株式会社 ヒトｔｓｈ及び犬ｔｓｈに対する抗体
WO2013119419A1 (fr) 2012-02-08 2013-08-15 North Carolina State University Traitement de maladies allergiques avec des anticorps recombinants
AR090915A1 (es) 2012-05-04 2014-12-17 Intervet Int Bv Proteina de fusion de proteina linfopoyetina estromal timica canina con la region fc de igg
EP2981280A2 (fr) * 2013-04-04 2016-02-10 IEO - Istituto Europeo di Oncologia Srl Fragments de lymphopoïétine stromale thymique et utilisations associées
TR201906969T4 (tr) * 2013-08-09 2019-06-21 Astellas Pharma Inc Yeni anti-insan tslp reseptör antikoru.
CN113173993B (zh) 2013-12-20 2024-03-08 英特维特国际股份有限公司 拮抗性抗犬pd-1抗体
WO2015118124A1 (fr) * 2014-02-06 2015-08-13 Vib Vzw Antagoniste du récepteur de la lymphopoïétine stromale thymique
CN107683291B (zh) 2015-04-02 2021-11-19 英特维特国际股份有限公司 针对犬白介素-4受体α的抗体
EP3842457A1 (fr) 2015-09-09 2021-06-30 Novartis AG Molécules de liaison de lymphopoïétine stromale thymique (tslp) et procédés d'utilisation des molécules
AU2016320748B2 (en) 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
CA3041717A1 (fr) 2016-11-09 2018-05-17 North Carolina State University Traitement de maladies allergiques au moyen d'une proteine chimerique
CN115028722A (zh) * 2021-03-05 2022-09-09 拜西欧斯（北京）生物技术有限公司 抗tslp抗体及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029581A1 (fr) * 1998-11-13 2000-05-25 Immunex Corporation Polypeptides de lymphopoietine de stroma thymique humain (tslp), adn et polypeptides associes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
ZA887773B (en) 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
US5714585A (en) 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US6844170B1 (en) 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US20030099947A1 (en) 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
WO2000039149A2 (fr) 1998-12-30 2000-07-06 Millennium Pharmaceuticals, Inc. Proteines secretees et leurs utilisations
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
JP2004519205A (ja) 2000-06-28 2004-07-02 アムジェン インコーポレイテッド 胸腺間質リンホポイエチンレセプター分子およびその使用
US6890734B2 (en) 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
ATE407691T1 (de) * 2003-07-18 2008-09-15 Schering Corp Behandlung und diagnose von neoplasien mit tslp (thymic stromal lymphopoietin)
CA2575721A1 (fr) * 2004-07-28 2006-03-02 Tanox, Inc. Promoteur de lymphopoietine stromale thymique et son utilisation
SE532251C2 (sv) * 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av TSLP för behandling av TH2-medierade inflammatoriska sjukdomar genom vaccinering
CA2671865C (fr) 2006-12-14 2017-01-10 Schering-Plough Ltd. Lymphopoietine stromale thymique (tslp) canine et utilisations associees

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029581A1 (fr) * 1998-11-13 2000-05-25 Immunex Corporation Polypeptides de lymphopoietine de stroma thymique humain (tslp), adn et polypeptides associes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [online] 1 December 2001 (2001-12-01), "Thymic stromal lymphopoietin precursor.", XP002482348, retrieved from EBI accession no. UNIPROT:Q969D9 Database accession no. Q969D9 *
LIU Y -J: "Thymic stromal lymphopoietin: Master switch for allergic inflammation", JOURNAL OF EXPERIMENTAL MEDICINE 20060220 US, vol. 203, no. 2, 20 February 2006 (2006-02-20), pages 269 - 273, XP002482347, ISSN: 0022-1007 0022-1007 *
QUENTMEIER H ET AL: "CLONING OF HUMAN THYMIC STROMAL LYMPHOPOIETIN (TSLP) AND SIGNALING MECHANISMS LEADING TO PROLIFERATION", LEUKEMIA, MACMILLAN PRESS LTD, US, vol. 15, no. 8, 1 August 2001 (2001-08-01), pages 1286 - 1292, XP001203456, ISSN: 0887-6924 *
RECHE P A ET AL: "Human thymic stromal lymphopoietin preferentially stimulates myeloid cells", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 167, no. 1, 1 July 2001 (2001-07-01), pages 336 - 343, XP002348557, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
RU2457217C2 (ru) 2012-07-27
KR20090097921A (ko) 2009-09-16
ZA200904152B (en) 2011-11-30
CA2671865C (fr) 2017-01-10
CN101631800B (zh) 2012-12-05
RU2012113162A (ru) 2013-10-20
RU2009126617A (ru) 2011-01-20
MX2009006470A (es) 2009-06-26
JP2012090647A (ja) 2012-05-17
NZ578352A (en) 2012-05-25
BRPI0720001A2 (pt) 2013-12-24
IL199170A (en) 2015-04-30
IN2009CN03372A (fr) 2015-08-07
EP2104683B1 (fr) 2016-05-25
CN101631800A (zh) 2010-01-20
KR101525631B1 (ko) 2015-06-04
UA108064C2 (uk) 2015-03-25
US20080152620A1 (en) 2008-06-26
UA120027C2 (uk) 2019-09-25
JP2013048637A (ja) 2013-03-14
CA2671865A1 (fr) 2008-06-26
US7718772B2 (en) 2010-05-18
WO2008076255A2 (fr) 2008-06-26
CN102584998B (zh) 2017-07-04
US8791242B2 (en) 2014-07-29
ES2582655T3 (es) 2016-09-14
US8076456B2 (en) 2011-12-13
JP5707380B2 (ja) 2015-04-30
JP6117767B2 (ja) 2017-04-19
IL215507A0 (en) 2011-11-30
JP2010512744A (ja) 2010-04-30
CO6210756A2 (es) 2010-10-20
EP2104683A2 (fr) 2009-09-30
US20130183291A1 (en) 2013-07-18
UA95329C2 (ru) 2011-07-25
RU2617957C2 (ru) 2017-04-28
AU2007334531B2 (en) 2012-04-12
JP2015107121A (ja) 2015-06-11
CN102584998A (zh) 2012-07-18
US20110033478A1 (en) 2011-02-10
AU2007334531A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
WO2008076255A3 (fr) Lymphopoïétine stromale thymique (tslp) canine et utilisations associées
PH12017501025A1 (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
WO2008145401A3 (fr) Protéines structurales de parvovirus mutées en tant que vaccins
WO2011032161A3 (fr) Vaccins dirigés contre les cellules de langerhans
WO2008006554A3 (fr) Anticorps modifiés
MY162752A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
WO2008098917A3 (fr) Nouveaux anticorps
WO2008005880A3 (fr) Anticorps anti-norovirus
WO2006085961A3 (fr) Anticorps anti-mcp-1, compositions, procedes et utilisations
WO2010046775A3 (fr) Procédés pour produire des anticorps à partir de plasmocytes
WO2010010466A3 (fr) Anticorps neutralisant anti-virus influenza a et leurs utilisations
WO2007018853A3 (fr) Secretion d'anticorps sans peptides de signal de bacterie
WO2006125202A3 (fr) Anticorps anti-mcp-1, compositions, methodes et utilisations correspondantes
WO2008130382A3 (fr) Protéines de fusion à base de cytokine pour le traitement de troubles immunitaires
WO2006135428A3 (fr) Methodes et compositions destinees a induire une reponse immunitaire contre des antigenes multiples
MX2010001237A (es) Nuevos anticuerpos.
WO2009109368A8 (fr) Identification de protéines de liaison spécifiques à un antigène ou à un ligand
EP1918302A3 (fr) Procédés d'identification et d'isolation d'anticorps spécifiques d'épitope
WO2011153400A3 (fr) Immunisation par voie nasale
WO2007030014A3 (fr) Recombinaison homologue dans les plantes
WO2007117763A3 (fr) Procédés et compositions destinés à cibler relt
WO2010009856A3 (fr) Protéine de liaison d’antigène goodpasture et sa détection
WO2007020520A3 (fr) Peptides antigeniques et leur utilisation
MX2009008754A (es) Anticuerpos novedosos contra igf-1r.
WO2006108658A3 (fr) Procede de production d'anticorps monoclonaux

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780051269.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007867705

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07867705

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2671865

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12009501169

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2009541349

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007334531

Country of ref document: AU

Ref document number: 3372/CHENP/2009

Country of ref document: IN

Ref document number: MX/A/2009/006470

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 09062338

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2007334531

Country of ref document: AU

Date of ref document: 20071211

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097014362

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 578352

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2009126617

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 215507

Country of ref document: IL

ENP Entry into the national phase

Ref document number: PI0720001

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090612